



(11)

EP 3 252 079 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 16/40 ^(2006.01) **A61K 39/395** ^(2006.01)
A61P 9/10 ^(2006.01) **A61P 27/02** ^(2006.01)

(48) Corrigendum issued on:
09.09.2020 Bulletin 2020/37

(45) Date of publication and mention
of the grant of the patent:
29.07.2020 Bulletin 2020/31

(21) Application number: **17169315.3**

(22) Date of filing: **05.04.2007**

(54) **ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTP-BETA) AND USES THEREOF**

AN DIE HUMANE PROTEINTYROSINPHOSPHATASE-BETA (HPTP-BETA) BINDENDE
ANTIKÖRPER UND ANWENDUNGEN DAVON

ANTICORPS SE LIANT À LA PROTÉINE TYROSINE PHOSPHATASE BÉTA HUMAINE (HPTP-BETA)
ET LEURS UTILISATIONS

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR**

(30) Priority: **07.04.2006 US 790506 P**
09.05.2006 US 798896 P

(43) Date of publication of application:
06.12.2017 Bulletin 2017/49

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
11155518.1 / 2 371 865
07735408.2 / 2 004 697

(73) Proprietor: **Aerpio Therapeutics LLC**
Cincinnati, OH 45242 (US)

(72) Inventors:
• **Rotello, Rocco Jamie**
Lebanon, OH 45036 (US)
• **Peters, Kevin**
Cincinnati, OH 45243 (US)

• **Davis, Michael Glenn**
Lebanon, OH 45036 (US)

(74) Representative: **Avidity IP**
Broers Building
Hauser Forum
21 JJ Thomson Avenue
Cambridge CB3 0FA (GB)

(56) References cited:
WO-A1-00/65085 US-A1- 2004 077 065

• **KRUEGER NX ET AL: "STRUCTURAL DIVERSITY
AND EVOLUTION OF HUMAN RECEPTOR-LIKE
PROTEIN TYROSINE PHASPHATASES", EMBO
(EUROPEAN MOLECULAR BIOLOGY
ORGANIZATION) JOURNAL, WILEY, DE, vol. 9,
no. 10, 1 October 1990 (1990-10-01), pages
3241-3252, XP002032773, ISSN: 0261-4189**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 252 079 B8

- **MUELLER SABINE ET AL: "Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy", EXPERT OPINION ON THERAPEUTIC TAR, INFORMA HEALTHCARE, UK, vol. 8, no. 3, 1 June 2004 (2004-06-01), pages 211-220, XP009093419, ISSN: 1472-8222, DOI: 10.1517/14728222.8.3.211**
- **Kimberly A Neely ET AL: "Commentary Ocular Neovascularization Clarifying Complex Interactions", , 1 September 1998 (1998-09-01), XP055414182, Retrieved from the Internet: URL:[http://ajp.amjpathol.org/article/S0002-9440\(10\)65607-6/pdf](http://ajp.amjpathol.org/article/S0002-9440(10)65607-6/pdf) [retrieved on 2017-10-10]**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification